Armando Sardi, M.D., F.A.C.S.
FIELD: Surgical Oncology, Cancer Surgery
POSITION/TITLE: Director, The Institute for Cancer Care at Mercy, head of Division of Surgical Oncology
BACKGROUND: Dr. Sardi is a surgical oncologist with a special interest in the treatment of intra-abdominal malignancies.
Dr. Sardi earned his M.D. in his native South America at the Universidad del Valle in Colombia. After graduation, he completed a one-year internship in Colombia and then moved on to a second internship at South Baltimore General Hospital. Thereafter, he enrolled in and completed residency programs at South Baltimore General and St. Agnes HealthCare.
Dr. Sardi completed his training as a fellow in oncologic surgery at The Ohio State University.
Dr. Sardi practiced as a surgical oncologist at the Ochsner Clinic in New Orleans, and was the founding Chief of Surgical Oncology at Health Care International in Glasgow. In 1994, he was named Chief of Surgical Oncology at St. Agnes Hospital in Baltimore and was later appointed Medical Director of the Clinical Research Center.
Honored by Baltimore Magazine in the publication’s annual “TOP DOCS” edition, Dr. Sardi joined Mercy Medical Center in Baltimore City in February 2006.
Dr. Sardi was named one of Columbia's 100 Most
Influential Expatriates and received a Presidential Honor from Columbia for the
work of his non-profit, Partners for Cancer Care and Prevention, which has
provided services to thousands of patients in Columbia.
MISCELLANEOUS: Dr. Sardi one of the select few surgical oncologists in the world who employs leading edge procedures such as HIPEC (Hyperthermic Intraperitoneal Chemotherapy) to treat advanced stages of abdominal cancers. Dr. Sardi has been performing HIPEC since 1994.
HIPEC is an aggressive surgical treatment reserved for patients with peritoneal surface malignancies. The procedure, which can take up to 15 hours to perform, combines the extensive removal of cancerous tumors with a highly concentrated dose of heated chemotherapy applied directly to the peritoneal cavity.
To raise funds and awareness regarding HIPEC and the fight against peritoneal cancers, Dr. Sardi has played a leadership role in Mercy’s annual “Heat It To Beat It” benefit walk held at Rash Field/Inner Harbor.
Dr. Sardi is currently a member of both the Scientific Council and the Editorial Board of Colombia Médica - Universidad del Valle, and Mercy Medical Center’s Scientific Review Committee. Since 2006, he has served as medical director of the hospital’s annual Colombia Medical Mission. Dr. Sardi is founder and president of Partners for Cancer Care and Prevention (formerly known as United Hands for Health, Inc.)
Sardi A. Peritoneal carcinomatosis: Not the end of the road. Presented at the Tumor Board at the University of Valle in Cali-Colombia, April 8, 2011.
El Halabi H, Ledakis P, Gushchin V, Francis J, Athas N, Macdonald R, Studeman K, Sardi A. The role of cytoreductive surgery in patients with carcinomatosis from high-grade appendix cancer in the era of modern systemic chemotherapy. Presented to ASCO Annual Meeting in Chicago, IL June 3-5, 2011
Sardi A. GI Neuroendocrine Tumors: A Team Approach. Presented to 3rd Annual Consensus and Controversies in Gastroenterology & Hepatology. Mercy Medical Center, Baltimore, MD September 23-24, 2011
Sardi A. Neuroendocrine Tumors: A Team Approach. Presented at Cancer Care: Back to Basics, A Comprehensive Look at A Multidisciplinary Approach in Treatment of Oncological Diseases. The Institute for Cancer Care at Mercy Medical Center, Baltimore, MD February 3, 2012
Basic General Surgery - Lower Porcine Program “Da Vinci Training” – Philadelphia, PA
El Halabi H, Gushchin V, Francis J, Athas N, MacDonald R, Nieroda C, Studeman K, Sardi A. The role of cytoreductive surgery and heated intraperitoneal chemotherapy (CRS/HIPEC) in patients with high-grade appendiceal cancer and extensive disease. Ann Surg Oncol (2012) 19:110-114
El Halabi H, Gushchin V, Francis J, MacDonald R, Athas N, Sardi A. Prognostic Significance of Lymph Node Metastases in Patients with High-grade Appendiceal Cancer. Ann Surg Oncol (2012) 19:122-125
El Halabi H, Ledakis P, Francis J, Athas N, MacDonald R., Studeman K, Wosu C, Nieroda C, Gushchin V, Sardi A. The Role of Systemic Chemotherapy in Patients Undergoing Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy for Carcinomatosis from Appendiceal Cancer. Submitted to J Surg Oncol. Oct. 2011
El Halabi H, Sardi A, MacDonald R, Studeman K, Francis J, Nieroda V, Gushchin V. Delay of Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy (CRS/HIPEC) in Patients with Appendiceal Neoplasm. Submitted to Am Surg Jan 2012
Thieme H, Gushchin V, Sardi A, Athas N. Peritoneal Carcinomatosis in the Geriatric Patient: Outcomes with Cytoreductive Surgery and HIPEC. Ann Surg Oncol. February 2010;17(1) 290: 123
El Halabi H, Gushchin V, Francis J, MacDonald R, Athas N, Sardi A. Lymph node metastasis predicts survival in patients with high-grade appendix cancer. Ann Surg Oncol. February 2011; 18(1) 154: 86
El Halabi H, Gushchin V, Francis J, MacDonald R, Sardi A. Patients with high-grade appendix cancer and extensive disease benefit from cytoreductive surgery and heated intraperitoneal chemotherapy. Ann Surg Oncol, February 2011; 18(1) 203: 101
El Halabi H, Gushchin V, Francis J, Nieroda C, Sardi A. The role of cytoreductive surgery in patients with carcinomatosis from high-grade appendix cancer in the era of modern systemic chemotherapy. J Clin Oncol 29: 2011 (suppl; abst 4080)
1Chua T, 2Moran B, 3Sugarbaker P, 4Levine E, 5Glehen O, 5Gilly F, 6Baratti D, 6Deraco M, 7Elias D, 8Sardi A, 1Liauw W, 3Yan T, 9Barrios P, 10Gómez Portilla A, 11de Hingh I, 12Ceelen W, 13Pelz J, 14Piso P, 15González-Moreno S, 16Van Der Speeten K, 1Morris D. Early and Long-term Outcome Data on 2298 Patients with Pseudomyxoma Peritonei of Appendiceal Origin Treated by a Strategy of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. J Clin Oncol 30, 2012 (suppl 4; abstr 532)
RECENTLY SUBMITTED ABSTRACTS:
Wosu C, El-Halabi, Wong M, Gallagher B, Francis J, Studeman K, Ledakis P, Nieroda C, Gushchin V, Sardi A. The Role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Patients with Primary Peritoneal Carcinoma. Submitted for presentation to Society for gynecologic Oncology Feb 2012 Winter Meeting
Wosu C, El-Halabi, Wong M, Gallagher B, Francis J, Studeman K, Ledakis P, Nieroda C, Gushchin V, Sardi A. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in the Management of High Grade Uterine Sarcomas with Peritoneal Dissemination. Submitted for presentation to Society for gynecologic Oncology Feb 2012 Winter Meeting.
El Halabi H, Gushchin V, Francis J, MacDonald R, Studeman K, Wosu C, Nieroda C, Sardi A. Port site metastases in patients with stage IV appendiceal neoplasm. Accepted by SSO for poster presentation at 65th Annual Symposium, March 2012, Orlando, Florida
Sardi A. Mercy Medical Center “Pilot Study" to Demonstrate the Link between H. Pylori and Development of Pseudomyxoma Peritonei (PMP). This study involves the evaluation of scientific data obtained from blood and tissue samples removed during cytoreductive surgery to determine the presence of various enteric bacteria (including H. Pylori). It further investigates the effects of antibiotics administered both pre and post surgery on the growth rate and recurrence of these tumors as well as patient survival. 2006 to present
Sardi A. Multi-center Selective Lymphadenectomy for Melanoma Trial II: A Phase III Multi-center Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients with Molecular or Histopathological Evidence of Metastases in the Sentinel Node. 2006 to present
Sardi A. Chemofx assay as a predictor of outcome in patients who have peritoneal carcinomatosis treated with cytoreductive surgery, intraperitoneal hyperthermic chemotherapy (IPHC) with Mitomycin C, with or without post IPHC chemotherapy. The assessment of the effectiveness of multiple chemotherapy agents on tumor tissue removed during cytoreductive surgery identifies the optimal chemotherapy agent most suited to effectively treat these cancerous tumors. 2007 to present
Sardi A. International PM Registry 2010. A world-wide, multi-institutional retrospective database creating the largest available dataset for a comparative study of conventional treatment versus radical cytoreduction with IP therapy for mucinous appendiceal cancer. This international registry is used for univariate and multivariate analysis of factors associated with survival. 2010 to present
Sardi A. A Study of Tissue Molecular Markers and Their Relationship to Treatment and Outcome in Appendiceal Cancer with Pseudomyxoma Peritonei (PMP). The objectives of this research are to determine the expression or mutations in the genes K-ras, EGFR, B-RAF, VEGF, ERCC1, HER 2/Neu, TS, as well as the status of MSI in tumor tissue from advanced appendiceal cancer and to study a potential association between those genes and tumor grade, and treatment outcome such as time to recurrence, overall and disease free survival after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy and systemic chemotherapy. 2010 to present